HUP0400231A3 - Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer - Google Patents
Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancerInfo
- Publication number
- HUP0400231A3 HUP0400231A3 HU0400231A HUP0400231A HUP0400231A3 HU P0400231 A3 HUP0400231 A3 HU P0400231A3 HU 0400231 A HU0400231 A HU 0400231A HU P0400231 A HUP0400231 A HU P0400231A HU P0400231 A3 HUP0400231 A3 HU P0400231A3
- Authority
- HU
- Hungary
- Prior art keywords
- deception
- immune
- cancer
- treatment
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29891501P | 2001-06-19 | 2001-06-19 | |
US10/108,511 US20030017134A1 (en) | 2001-06-19 | 2002-03-29 | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
PCT/IL2002/000478 WO2002102299A2 (en) | 2001-06-19 | 2002-06-18 | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400231A2 HUP0400231A2 (hu) | 2005-05-30 |
HUP0400231A3 true HUP0400231A3 (en) | 2010-11-29 |
Family
ID=26805971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400231A HUP0400231A3 (en) | 2001-06-19 | 2002-06-18 | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
Country Status (11)
Country | Link |
---|---|
US (1) | US20030017134A1 (hu) |
EP (1) | EP1409547B1 (hu) |
JP (1) | JP5148804B2 (hu) |
CA (1) | CA2451353C (hu) |
CZ (1) | CZ200479A3 (hu) |
DK (1) | DK1409547T3 (hu) |
ES (1) | ES2652017T3 (hu) |
HU (1) | HUP0400231A3 (hu) |
NZ (2) | NZ530656A (hu) |
PL (1) | PL373302A1 (hu) |
WO (1) | WO2002102299A2 (hu) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645743B2 (en) * | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
CA2328356A1 (en) * | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
CA2404489A1 (en) * | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
US8022190B2 (en) | 2001-06-19 | 2011-09-20 | Technion Research & Development Foundation Ltd. | Immuno-molecules containing viral proteins, compositions thereof and methods of using |
GB2408507B (en) * | 2003-10-06 | 2005-12-14 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof for specific targeting |
EP2332971B1 (en) | 2004-06-17 | 2016-02-17 | MannKind Corporation | Epitope analogs |
KR20080028938A (ko) * | 2005-06-17 | 2008-04-02 | 맨카인드 코포레이션 | 에피토프 유사체 |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
KR101442209B1 (ko) * | 2006-05-19 | 2014-11-18 | 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. | 융합 단백질, 이의 용도 및 이의 제조방법 |
JP2012526130A (ja) * | 2009-05-05 | 2012-10-25 | アルテルムネ テクフノロジエス,エルエルシー | 化学的にプログラム可能な免疫 |
GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
ES2667864T3 (es) * | 2011-06-22 | 2018-05-14 | F. Hoffmann-La Roche Ag | Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I |
BR112014020119A2 (pt) | 2012-02-13 | 2020-10-27 | Gamida-Cell Ltd | cultura de células-tronco mesenquimais |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
JP2015537043A (ja) * | 2012-11-30 | 2015-12-24 | ロシュ グリクアート アーゲー | 多機能タンパク質を含むがん細胞標的化mhcクラスiを用いた循環性ウイルス特異的細胞傷害性t細胞によるがん細胞の除去 |
AU2013359907B2 (en) | 2012-12-11 | 2018-01-18 | Albert Einstein College Of Medicine, Inc. | Methods for high throughput receptor:ligand identification |
MX361076B (es) * | 2012-12-21 | 2018-11-27 | Hoffmann La Roche | Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro. |
WO2014127220A1 (en) | 2013-02-15 | 2014-08-21 | The Johns Hopkins University | Antigen-specific t cell redirectors |
CA2936352A1 (en) * | 2014-01-21 | 2015-07-30 | Albert Einstein College Of Medicine, Inc. | Cellular platform for rapid and comprehensive t-cell immunomonitoring |
WO2017201131A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
EP3458096A4 (en) | 2016-05-18 | 2019-11-27 | Cue Biopharma, Inc. | T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE |
JP2019517499A (ja) | 2016-06-02 | 2019-06-24 | イムノコア リミテッド | gp100特異的TCR−抗CD3 scFv融合タンパク質の投薬レジメン |
IL297617B2 (en) | 2016-12-22 | 2023-11-01 | Cue Biopharma Inc | Multimeric polypeptides modulate T cells and methods for their use |
EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
AU2018234628B2 (en) | 2017-03-15 | 2023-07-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
WO2019036688A1 (en) * | 2017-08-18 | 2019-02-21 | Gritstone Oncology, Inc. | ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS |
CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
WO2019162937A1 (en) * | 2018-02-20 | 2019-08-29 | Technion Research & Development Foundation Limited | Immunotherapeutic composition for the treatment of cancer |
EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma Inc | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
WO2023126544A1 (en) * | 2022-01-03 | 2023-07-06 | Aarhus Universitet | Proteinaceous compound for generating specific cytotoxic t-cell effect |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
US5194425A (en) * | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
DE3825615A1 (de) * | 1988-07-28 | 1990-02-01 | Behringwerke Ag | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
US5976551A (en) * | 1991-11-15 | 1999-11-02 | Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale | Altered major histocompatibility complex (MHC) determinant and method of using the determinant |
US5837477A (en) * | 1993-01-15 | 1998-11-17 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptor ligands and methods of using same |
US5820866A (en) * | 1994-03-04 | 1998-10-13 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for T cell regulation |
US5635363A (en) * | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
WO1997024446A2 (en) * | 1995-12-29 | 1997-07-10 | Chiron Corporation | Gene delivery vehicle-targeting ligands |
US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
US6015884A (en) * | 1996-03-28 | 2000-01-18 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6140113A (en) * | 1996-03-28 | 2000-10-31 | The Johns Hopkins University | Polynucleotides encoding molecular complexes which modify immune responses |
US6211342B1 (en) * | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
US6232445B1 (en) * | 1997-10-29 | 2001-05-15 | Sunol Molecular Corporation | Soluble MHC complexes and methods of use thereof |
US6235445B1 (en) * | 1998-04-15 | 2001-05-22 | Fuji Photo Film Co., Ltd. | Thermal transfer sheet |
GB2339782A (en) * | 1998-06-05 | 2000-02-09 | Philip Michael Savage | Chimeric protein complexes comprising HLA class I antigens |
CA2404489A1 (en) * | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
JP2003530836A (ja) * | 2000-04-12 | 2003-10-21 | ユニバーシティー オブ ロチェスター | 標的化ワクチン送達システム |
AU2001271273A1 (en) * | 2000-05-24 | 2001-12-03 | Ludwig Institute For Cancer Research | Multicomponent conjugates which bind to target molecules and stimulate cell lysis |
GB0026812D0 (en) * | 2000-11-02 | 2000-12-20 | Isis Innovation | Cancer therapy |
-
2002
- 2002-03-29 US US10/108,511 patent/US20030017134A1/en not_active Abandoned
- 2002-06-18 EP EP02733206.3A patent/EP1409547B1/en not_active Expired - Lifetime
- 2002-06-18 NZ NZ530656A patent/NZ530656A/en not_active IP Right Cessation
- 2002-06-18 CZ CZ200479A patent/CZ200479A3/cs unknown
- 2002-06-18 CA CA2451353A patent/CA2451353C/en not_active Expired - Fee Related
- 2002-06-18 NZ NZ581793A patent/NZ581793A/en not_active IP Right Cessation
- 2002-06-18 PL PL02373302A patent/PL373302A1/xx not_active Application Discontinuation
- 2002-06-18 ES ES02733206.3T patent/ES2652017T3/es not_active Expired - Lifetime
- 2002-06-18 WO PCT/IL2002/000478 patent/WO2002102299A2/en active Application Filing
- 2002-06-18 DK DK02733206.3T patent/DK1409547T3/en active
- 2002-06-18 HU HU0400231A patent/HUP0400231A3/hu unknown
- 2002-06-18 JP JP2003504888A patent/JP5148804B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20030017134A1 (en) | 2003-01-23 |
CA2451353A1 (en) | 2002-12-27 |
EP1409547B1 (en) | 2017-09-20 |
CA2451353C (en) | 2012-01-17 |
CZ200479A3 (cs) | 2004-11-10 |
EP1409547A4 (en) | 2007-05-02 |
HUP0400231A2 (hu) | 2005-05-30 |
WO2002102299A2 (en) | 2002-12-27 |
PL373302A1 (en) | 2005-08-22 |
WO2002102299A3 (en) | 2003-11-27 |
ES2652017T3 (es) | 2018-01-31 |
DK1409547T3 (en) | 2018-01-08 |
JP5148804B2 (ja) | 2013-02-20 |
NZ530656A (en) | 2007-05-31 |
NZ581793A (en) | 2010-07-30 |
JP2005506058A (ja) | 2005-03-03 |
EP1409547A2 (en) | 2004-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400231A3 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
AU6147401A (en) | Compositions and methods for the treatment of cancer | |
IL157993A0 (en) | Molecular conjugates for use in cancer treatment and methods for the preparation thereof | |
IL231810A (en) | History of itensinoid and pharmaceutical preparations containing the same methods of preparation and use thereof for cancer treatment | |
PL370029A1 (en) | 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer | |
EP1355563A4 (en) | METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES | |
KR100510795B1 (en) | Compositions and Methods for the Treatment of Tumor | |
EP1572118A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216 | |
MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
AU2001245295A1 (en) | Methods and compositions for the identification, assessment, prevention and therapy of human cancers | |
IL153359A0 (en) | Peptides, compositions and methods for the treatment of burkholderia cepacia | |
IL158206A0 (en) | Compositions and methods for the prevention and treatment of human prostate cancer | |
IL145397A0 (en) | Compositions and methods for treatment of cancer | |
PL368035A1 (en) | Compositions and methods for the treatment of cancer | |
AU2001238493A1 (en) | Methods and compositions for the identification, assessment, prevention and therapy of human cancers | |
EP1472273A4 (en) | COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES | |
IL160722A0 (en) | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | |
AU2002337713A1 (en) | Pharmaceutical compositions and methods for treating cancer | |
WO2002066492A3 (fr) | Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques. | |
AU2003219664A1 (en) | Methods and therapeutic compositions in the treatment of advanced cancer | |
IL160412A0 (en) | Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer | |
AU2001255168A1 (en) | Compositions and methods for the treatment of immune related diseases | |
AU2001245939A1 (en) | Compositions and methods for the identification, assessment, prevention, and therapy of human cancers | |
AU2003285125A8 (en) | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor | |
AU2002360454A8 (en) | Methods and compositions for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |